Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.81 |
| ▸ | CCND1 | P24385 | 4/20 | 0.81 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4554026 | 1.00 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL30376 | 0.98 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL29767815 | 0.98 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL19748097 | 0.98 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL31454116 | 0.98 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL28107377 | 0.98 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL4976386 | 0.98 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL29374771 | 0.94 | CDK4 (0.78) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL464099 | 0.94 | CDK4 (0.78) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL15924634 | 0.89 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118546235-A | Synthetic cannabinoid UR-144 antigen and preparation method thereof | 浙江隆基生物技术有限公司 | 2024-08-27 | — | — | CN | claimed |
| EP-4486336-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-118546235-A | Synthetic cannabinoid UR-144 antigen and preparation method thereof | 浙江隆基生物技术有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2023168296-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
| CN-112946089-B | Method for determining content and/or molecular structure of nitride in diesel oil | 中国石油化工股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | CDK4 2566/4885CCND1 4193/4885HTR2A 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.